公开(公告)号：US20170067115A1

公开(公告)日：2017-03-09

申请号：US15120052

申请日：2015-02-18

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Ajay GOEL ,  Lucia PEREZ-CARBONELL ,  C. Richard BOLAND

IPC: C12Q1/68 ,  C12N15/113 ,  G06F19/00 ,  A61K31/513

CPC classification number: C12Q1/6886 ,  A61K31/513 ,  C12N15/113 ,  C12N2310/14 ,  C12N2320/30 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178 ,  G06F19/00 ,  G16H10/60 ,  G16H40/63 ,  Y02A90/22 ,  Y02A90/26

Abstract: Embodiments provide methods and compositions related to determining treatments for colorectal cancer patients by detection and analysis of the expression level of miRNA such as miR-320e in the patients. Embodiments provide predictive, prognostic and/or diagnostics methods by identifying miRNAs that are useful for clinical management of cancer patients, particularly colorectal cancer patients or patients at risk or determined to have colorectal cancer. Methods and compositions are based, in part, on the discovery that expression of certain miRNAs in cancer patients is associated with advancing cancer stages and/or can predict the responsiveness of cancer therapy, and can, therefore, provide basis for designing treatment strategies. In particular embodiments, the miRNA molecule is miR-320, particularly miR-320e.

Abstract translation: 实施例提供了通过检测和分析患者诸如miR-320e之类的miRNA的表达水平来确定结肠直肠癌患者治疗相关的方法和组合物。 实施例通过鉴定可用于临床治疗癌症患者，特别是结肠直肠癌患者或处于风险中或确定为结肠直肠癌的患者的miRNA来提供预测，预后和/或诊断方法。 方法和组合部分地基于发现癌症患者中某些miRNA的表达与癌症阶段的进展和/或可以预测癌症治疗的反应性相关联，并且因此可以为设计治疗策略提供依据。 在具体实施方案中，miRNA分子是miR-320，特别是miR-320e。